Luoxin Pharmaceuticals Group Stock Co Ltd Market Cap ($649.33 Million)
Market Cap & Net Worth: Luoxin Pharmaceuticals Group Stock Co Ltd (002793)
Luoxin Pharmaceuticals Group Stock Co Ltd market cap. Luoxin Pharmaceuticals Group Stock Co Ltd (SHE:002793) has a market capitalization of $649.33 Million (CN¥4.44 Billion) as of November 6, 2026. Listed on the SHE stock exchange, this China-based company holds position #10650 globally and #2850 in its home market, demonstrating a 1.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Luoxin Pharmaceuticals Group Stock Co Ltd's stock price CN¥4.08 by its total outstanding shares 1087588486 (1.09 Billion). Also see 002793 cash flow conversion for how efficiently the company converts equity into cash flow.
Luoxin Pharmaceuticals Group Stock Co Ltd Market Cap History (2016–2026)
Luoxin Pharmaceuticals Group Stock Co Ltd market cap history from 2016 to 2026. Data shows change from $2.95 Billion to $649.33 Million (-1.55% CAGR). Check Luoxin Pharmaceuticals Group Stock Co Lt (002793) share price today for real-time trading data and today's change.
Luoxin Pharmaceuticals Group Stock Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Luoxin Pharmaceuticals Group Stock Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Luoxin Pharmaceuticals Group Stock Co Lt to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.34x
Luoxin Pharmaceuticals Group Stock Co Ltd's market cap is 0.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.95 Billion | $4.12 Billion | $379.20 Million | 0.72x | 7.78x |
| 2017 | $1.38 Billion | $828.04 Million | $115.85 Million | 1.67x | 11.92x |
| 2018 | $922.62 Million | $6.21 Billion | $512.32 Million | 0.15x | 1.80x |
| 2019 | $2.12 Billion | $7.59 Billion | $633.95 Million | 0.28x | 3.35x |
| 2020 | $1.64 Billion | $6.10 Billion | $320.70 Million | 0.27x | 5.10x |
| 2021 | $1.65 Billion | $6.48 Billion | $406.10 Million | 0.25x | 4.05x |
| 2022 | $1.22 Billion | $3.59 Billion | -$1.22 Billion | 0.34x | N/A |
| 2023 | $853.04 Million | $2.36 Billion | -$661.14 Million | 0.36x | N/A |
| 2024 | $607.95 Million | $2.65 Billion | -$965.50 Million | 0.23x | N/A |
| 2025 | $763.91 Million | $2.27 Billion | -$288.58 Million | 0.34x | N/A |
Competitor Companies of 002793 by Market Capitalization
Companies near Luoxin Pharmaceuticals Group Stock Co Ltd in the global market cap rankings as of November 6, 2026. Also see how large is Luoxin Pharmaceuticals Group Stock Co Lt's balance sheet for a full breakdown of the balance sheet.
Key companies related to Luoxin Pharmaceuticals Group Stock Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Luoxin Pharmaceuticals Group Stock Co Ltd (2016–2026)
Market capitalization of Luoxin Pharmaceuticals Group Stock Co Ltd from 2016 to today. Between 2016 and today, Luoxin Pharmaceuticals Group Stock Co Ltd's market cap moved from $2.95 Billion to $ 649.33 Million, with a yearly change of -1.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥649.33 Million | -15.00% |
| 2025 | CN¥763.91 Million | +25.65% |
| 2024 | CN¥607.95 Million | -28.73% |
| 2023 | CN¥853.04 Million | -30.12% |
| 2022 | CN¥1.22 Billion | -25.82% |
| 2021 | CN¥1.65 Billion | +0.52% |
| 2020 | CN¥1.64 Billion | -22.89% |
| 2019 | CN¥2.12 Billion | +130.10% |
| 2018 | CN¥922.62 Million | -33.17% |
| 2017 | CN¥1.38 Billion | -53.21% |
| 2016 | CN¥2.95 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Luoxin Pharmaceuticals Group Stock Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $649.33 Million USD |
| MoneyControl | $649.33 Million USD |
| MarketWatch | $649.33 Million USD |
| marketcap.company | $649.33 Million USD |
| Reuters | $649.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Luoxin Pharmaceuticals Group Stock Co Ltd
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, production, and sales of pharmaceutical products in China. The company provides anti-infective active pharmaceutical ingredients(APIs), antiviral APIs, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic… Read more